Vol. 284, Issue 1, 189-195, 1998

ONO-4007, an Antitumor Lipid A Analog, Induces Tumor Necrosis Factor- Production by Human Monocytes Only under Primed State: Different Effects of ONO-4007 and Lipopolysaccharide on Cytokine Production

Norihito Matsumoto, Yoshiya Aze, Akira Akimoto and Tsuneo Fujita

Fukui Research Institute, Ono Pharmaceutical Co., Ltd., Fukui, Japan

ONO-4007 is a synthetic lipid A analog that exhibits strong antitumor activity in several animal models via intratumoral production of tumor necrosis factor (TNF). In the present study, the cytokine-inducing effect of ONO-4007 was investigated in human monocytes that were freshly isolated or had been incubated for 3 days with granulocyte-macrophage colony-stimulating factor (GM-CSF) or macrophage colony-stimulating factor. ONO-4007 induced slight production of TNF-, Interleukin (IL)-1, IL-6 and IL-12 in fresh monocytes but strongly induced TNF- production in GM-CSF-treated monocytes. Monocytes treated with macrophage colony-stimulating factor were also primed to produce TNF- in response to ONO-4007. In the production of IL-1, IL-6 and IL-12, GM-CSF did not show a priming effect. In contrast to ONO-4007, lipopolysaccharide (LPS) induced significant amounts of all these cytokines in fresh monocytes. In whole blood, ONO-4007 failed to induce TNF-, whereas LPS and LA-15-PP (Escherichia coli-type lipid A) strongly induced TNF- production. In the GM-CSF-treated monocytes, both elimination of serum from the culture medium and anti-CD14 antibody treatment attenuated LPS-induced TNF- production but not ONO-4007-induced TNF- production. This study shows that ONO-4007 activates human monocytes/macrophages to release TNF- only in a primed state and suggests that ONO-4007 would activate these cells via different pathways from LPS. These differences could mean that ONO-4007 has potent antitumor activity with lower toxicity than LPS.